Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E. Chiesa C, et al. Cancer Biother Radiopharm. 2007 Feb;22(1):113-20. doi: 10.1089/cbr.2007.302. Cancer Biother Radiopharm. 2007. PMID: 17627419 Clinical Trial.
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM. Devizzi L, et al. Among authors: chiesa c. J Clin Oncol. 2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922. Epub 2013 Jul 15. J Clin Oncol. 2013. PMID: 23857974 Free PMC article. No abstract available.
Pretreatment Dosimetry in HCC Radioembolization with (90)Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of (99m)Tc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres.
Chiesa C, Lambert B, Maccauro M, Ezziddin S, Ahmadzadehfar H, Dieudonné A, Cremonesi M, Konijnenberg M, Lassmann M, Pettinato C, Strigari L, Vanderlinden B, Crippa F, Flamen P, Garin E. Chiesa C, et al. J Nucl Med. 2014 Jul;55(7):1215-6. doi: 10.2967/jnumed.113.129361. Epub 2014 Jun 4. J Nucl Med. 2014. PMID: 24898027 Free article. No abstract available.
Intrahepatic flow redistribution in patients treated with radioembolization.
Spreafico C, Morosi C, Maccauro M, Romito R, Lanocita R, Civelli EM, Sposito C, Bhoori S, Chiesa C, Frigerio LF, Lorenzoni A, Cascella T, Marchianò A, Mazzaferro V. Spreafico C, et al. Among authors: chiesa c. Cardiovasc Intervent Radiol. 2015 Apr;38(2):322-8. doi: 10.1007/s00270-014-0921-2. Epub 2014 Jun 14. Cardiovasc Intervent Radiol. 2015. PMID: 24927964
The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.
Verburg FA, Luster M, Giovanella L, Lassmann M, Chiesa C, Chouin N, Flux G; EANM Thyroid, Radiation Protection and Dosimetry Committees. Verburg FA, et al. Among authors: chiesa c. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):915-917. doi: 10.1007/s00259-017-3649-9. Epub 2017 Feb 16. Eur J Nucl Med Mol Imaging. 2017. PMID: 28210770 No abstract available.
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.
Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Cremonesi M, et al. Among authors: chiesa c. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514 Free PMC article. Review.
273 results